Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Daver on Results of a Combination Study With Azacitidine/Nivolumab in AML

March 6th 2020

Naval G. Daver, MD, discusses the results of a phase Ib/II study that evaluated the combination of azacitidine and nivolumab (Opdivo) in patients with relapsed/refractory acute myeloid leukemia.

Dr. Grossbard on the Utility of PI3K Inhibitors in Follicular Lymphoma

March 5th 2020

Michael L. Grossbard, MD, discusses the utility of PI3K inhibitors in follicular lymphoma.

Duvelisib Tested in Rare Lymphoma Subtype

March 4th 2020

Investigators propose that a PI3K-δ,γ inhibitor currently indicated for the treatment of 3 hematologic malignancies may be a key to boosting response rates in peripheral T-cell lymphoma, a disease setting defined by poor prognoses.

Oncology Community Mourns the Death of Clara D. Bloomfield

March 4th 2020

Clara D. Bloomfield, MD, the 2015 Giants of Cancer® award winner for Myeloid Neoplasms and a revolutionary physician-scientist, died March 1 at the age of 77.

Dr. Richardson on the FDA Approval of Isatuximab in Relapsed/Refractory Myeloma

March 3rd 2020

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the FDA approval of isatuximab-irfc (Sarclisa) for use in combination with pomalidomide (Pomalyst) and dexamethasone in relapsed/refractory multiple myeloma.

Breathing New Life Into Chemotherapy

March 2nd 2020

Although the development of chemotherapy-free regimens is a major thrust of oncology research, improvements to traditional cytotoxic therapy are actively being explored, with a focus on new formulations and delivery methods for agents that have been used for decades.

FDA Grants Priority Review to Tafasitamab/Lenalidomide Combo for Relapsed/Refractory DLBCL

March 2nd 2020

The FDA has granted a priority review designation to a biologics license application for the combination of tafasitamab and lenalidomide for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Venetoclax Combo Misses OS Endpoint in Phase III Frontline AML Trial

March 2nd 2020

Combining venetoclax with low-dose cytarabine (LDAC) did not lead to a statistically significant improvement in overall survival compared with LDAC alone in newly-diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy, according to findings from the phase III VIALE-C (M16-043) trial.

Pembrolizumab Improves PFS in Relapsed/Refractory Hodgkin Lymphoma

March 2nd 2020

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin in adult patients with relapsed/refractory classic Hodgkin lymphoma, meeting one of the dual primary endpoints of the phase III KEYNOTE-204 trial.

Next Chapter Begins With CAR T-Cell Therapy in Myeloma

March 1st 2020

Noopur Raje, MD, discusses the investigational CAR T-cell therapies and strategies in the multiple myeloma pipeline.

Unmet Needs Remain in GVHD, But Novel Approaches on Horizon

March 1st 2020

Corey S. Cutler, MD, MPH, discusses how physicians can optimize treatment management in patients with both acute and chronic graft-versus-host-disease.

Dr. Radich on the Evolving Role of MRD in Hematologic Malignancies

March 1st 2020

Jerald P. Radich, MD, discusses how the role of minimal residual disease (MRD) has evolved recently in clinical trials of hematologic malignancies.

Deep Data Dive Needed for Upfront Treatment Selection in iNHL

February 29th 2020

At the 24th Annual International Congress on Hematologic Malignancies®, Sonali M. Smith, MD, detailed the critical clinical trial findings currently informing treatment selection in the frontline indolent non-Hodgkin lymphoma paradigm.

Experts Share Common Misconceptions in Their Fields

February 29th 2020

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

Dr. Cortes on Tyrosine Kinase Inhibitors in CML

February 29th 2020

Jorge E. Cortes, MD, shares his experience with tyrosine kinase inhibitors as treatment of patients with chronic myeloid leukemia.

Dr. Khaled on Recognition and Treatment of TA-TMA

February 29th 2020

Samer K. Khaled, MD, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy.

Dr. Ramakrishnan on Updates in DLBCL

February 29th 2020

Praveen Ramakrishnan, MD, assistant professor, Department of Internal Medicine, UT Southwestern Medical Center, discusses updates in diffuse large B-cell lymphoma (DLBCL) that were presented at the 2019 ASH Annual Meeting.

Dr. Heyman on the Use of Maintenance Rituximab in Follicular Lymphoma

February 29th 2020

Benjamin Heyman, MD, assistant clinical professor of medicine, University of California, San Diego, discusses the use of maintenance rituximab (Rituxan) in patients with follicular lymphoma.

Expanded Choices Emerge for Myelofibrosis Following Ruxolitinib Therapy

February 29th 2020

Newly approved and investigational agents are joining ruxolitinib for the treatment of myelofibrosis and may provide options for patients who progress or become intolerant to frontline JAK inhibitors.

Park Touts Further Developments, Unmet Needs With CAR T-Cell Therapy in ALL

February 28th 2020

Jae H. Park, MD, discusses the challenges in using CAR T-cell therapy in adult patients with acute lymphoblastic leukemia, and also highlights the potential role for off-the-shelf CAR T cells.